CN109045184A - A kind of preparation method treated coronary heart disease and exhaust fragrant analgesic therapy capsule - Google Patents
A kind of preparation method treated coronary heart disease and exhaust fragrant analgesic therapy capsule Download PDFInfo
- Publication number
- CN109045184A CN109045184A CN201811034887.0A CN201811034887A CN109045184A CN 109045184 A CN109045184 A CN 109045184A CN 201811034887 A CN201811034887 A CN 201811034887A CN 109045184 A CN109045184 A CN 109045184A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart disease
- coronary heart
- analgesic therapy
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of preparation methods treated coronary heart disease and exhaust fragrant analgesic therapy capsule, specifically includes the following steps: taking formula ratio Resina Draconis part, santal, ginseng, Poria cocos, asarum, borneol, amber and Radix Notoginseng milling are sieved and uniformly mix, mixed powder is added appropriate maltodextrin and mixes again simultaneously, subsequent dry-pressing granulation, then Magnesium Stearate proper quantity is added, it is encapsulated, 0.5g/, unstable angina pectoris of coronary heart disease patient c reactive protein and low-density lipoprotein are had a significant impact according to pharmaceutical capsules prepared by the present invention, without obvious adverse reaction, the clinical symptoms and prognosis that can more effectively improve patient are shared with modern Western medicine treatment, be conducive to the Morbidity control of unstable angina, its anti-inflammatory effect may be by improving endothelial function and blood coagulation state, reduce the expression and generation of inflammatory mediator and cell factor And achievees the purpose that inhibit inflammation, stablizes patch.
Description
Technical field
The present invention relates to field of medicaments, exhaust fragrant analgesic therapy capsule and preparation method thereof more particularly, to a kind of coronary heart disease for the treatment of.
Background technique
Coronary atherosclerotic heart disease is that coronary artery occurs atherosclerotic lesion and causes blood vessel
Chamber stenosis or occlusion causes heart disease, commonly referred to as " coronary heart disease " caused by myocardial ischemia, anoxic or necrosis.But it is preced with
The range of heart trouble may further include more extensively that inflammation, embolism etc. lead to luminal stenosis or occlusion.The World Health Organization is by coronary heart disease
It is divided into 5 major class: silent ischemia (latent coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic
Heart disease) and 5 kinds of Clinical types of sudden death.Usually it is divided into stable coronary heart disease and acute coronary syndrome in clinic.
Drug currently used for coronary heart disease treatment is mostly Western medicine, integrally there is weak curative effect, the big disadvantage of side effect,
Summary of the invention
The present invention is to overcome above situation insufficient, it is desirable to provide a kind of technical solution that can solve the above problem.
A kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following components: 10-15 parts of Resina Draconis, santal
5-8 parts, 5-8 parts of ginseng, 10-14 parts of Poria cocos, 4-6 parts of asarum, 1-3 parts of borneol, 5-7 parts of amber, 10-18 parts of Radix Notoginseng.
As a further solution of the present invention: a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following
Component: 10 parts of Resina Draconis, 5 parts of santal, 5 parts of ginseng, 10 parts of Poria cocos, 4 parts of asarum, 1 part of borneol, 5 parts of amber, 10 parts of Radix Notoginseng.
As a further solution of the present invention: a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following
Component: 15 parts of Resina Draconis, 8 parts of santal, 8 parts of ginseng, 14 parts of Poria cocos, 6 parts of asarum, 3 parts of borneol, 7 parts of amber, 18 parts of Radix Notoginseng.
As a further solution of the present invention: a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following
Component: 14 parts of Resina Draconis, 7 parts of santal, 7 parts of ginseng, 9 parts of Poria cocos, 5 parts of asarum, 2 parts of borneol, 6 parts of amber, 15 parts of Radix Notoginseng.
As a further solution of the present invention: a kind of preparation method treated coronary heart disease and exhaust fragrant analgesic therapy capsule specifically includes
Following steps: taking formula ratio Resina Draconis part, santal, ginseng, Poria cocos, asarum, borneol, and amber and the sieving of Radix Notoginseng milling are simultaneously uniform
Mixing, while mixed powder is added appropriate maltodextrin and mixes again, then subsequent dry-pressing granulation adds Magnesium Stearate proper quantity,
It is encapsulated, 0.5g/.
Beneficial effects of the present invention: through after exhausting fragrant analgesic therapy capsule for treating blood CRP level be decreased obviously, to coronary heart disease shakiness
Sizing patient with angina pectoris c reactive protein and low-density lipoprotein have a significant impact.Without obvious adverse reaction, treated with modern Western medicine
Share the clinical symptoms and prognosis that can more effectively improve patient.This research prompt exhausts fragrant analgesic therapy capsule in the effect machine of anti-inflammatory aspect
It is formed with the Morbidity control conducive to unstable angina, anti-inflammatory effect may be by improving endothelial function and blood coagulation shape
The expression of state, reduction inflammatory mediator and cell factor achievees the purpose that inhibit inflammation, stable patch with generating.
Additional aspect and advantage of the invention will be set forth in part in the description, and will partially become from the following description
Obviously, or practice through the invention is recognized.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
In the embodiment of the present invention 1, a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following components: dragon
10-15 parts of dragon's blood, 5-8 parts of santal, 5-8 parts of ginseng, 10-14 parts of Poria cocos, 4-6 parts of asarum, 1-3 parts of borneol, 5-7 parts of amber, three
Seven 10-18 parts.
In the embodiment of the present invention 2, a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following components: dragon
10 parts of dragon's blood, 5 parts of santal, 5 parts of ginseng, 10 parts of Poria cocos, 4 parts of asarum, 1 part of borneol, 5 parts of amber, 10 parts of Radix Notoginseng.
In the embodiment of the present invention 3, a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following components: dragon
15 parts of dragon's blood, 8 parts of santal, 8 parts of ginseng, 14 parts of Poria cocos, 6 parts of asarum, 3 parts of borneol, 7 parts of amber, 18 parts of Radix Notoginseng.
In the embodiment of the present invention 4, a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, by weight includes following components: dragon
14 parts of dragon's blood, 7 parts of santal, 7 parts of ginseng, 9 parts of Poria cocos, 5 parts of asarum, 2 parts of borneol, 6 parts of amber, 15 parts of Radix Notoginseng.
A kind of coronary heart disease for the treatment of exhausts the preparation method of fragrant analgesic therapy capsule, specifically includes the following steps: taking formula ratio Resina Draconis
Part, santal, ginseng, Poria cocos, asarum, borneol, amber and Radix Notoginseng milling are sieved and uniformly mix, while mixed powder is added in right amount
Maltodextrin mixes again, then subsequent dry-pressing granulation adds Magnesium Stearate proper quantity, encapsulated, and 0.5g/.
This prescription drug is removed obstruction in channels to relieve pain major function: blood-activating and qi-promoting, is mainly used for card and is belonged to coronary disease caused by blood stasis type
The cards such as disease, hypertension, myocarditis, Cardianeuropathy, hypercoagulable blood are shown in precordialgia, uncomfortable in chest, shortness of breath, out of strength, palpitaition etc..Side
Solution: ginseng in side, Poria cocos strengthening the spleen and replenishing qi, promoting blood circulation row arteries and veins, with up to the function of gas row then blood；The promoting blood circulations such as Resina Draconis, amber, Radix Notoginseng are logical
Network analgesic；Borneol, santal fragrance qi-regulating；The promoting blood circulation of asarum warming yang for activating qi-flowing；Full side is played altogether adjusts spleen shield heart, and the function of Warming Yang and promoting blood circulation has
Treating both manifestation and root cause of disease feature.
The actual efficacy of this formula is verified below with reference to actual therapeutic.
1. data and method
1.1 research object selected cases are all from Tianshui hospital of traditional Chinese hospital Internal Medicine-Cardiovascular Dept. in April, 2008~2010 year 1
Inpatient during month, totally 150, is randomly divided into two groups, wherein observation group 90, and control group 60, wherein male 96, female 54
Example；Age between 40~75 years old, average age 64.1 years old.Two groups of genders, age, the course of disease and card type distribution aspect are without obvious poor
It is different, it is comparable (P > 0.05).Concrete condition is shown in Table 1, table 2.
1 two groups of basic conditions of table compare
2 two groups of card type distribution situations of table compare (example):
1.2 object selection criteria
1.2.1 the diagnostic criteria of unstable angina pectoris of coronary heart disease is defended referring to International Society of Cardiology and association and the world
Raw the specialist paper of tissue naming standard joint " name and diagnostic criteria of ischemic heart disease ".
1.2.2 the CM syndrome differentiation criterion of unstable angina pectoris of coronary heart disease was referring to version " new Chinese medicine clinical research guidance in 2002
Principle, selected patients according to respective primary symptom and minor symptom feature, according to 3 stagnation of the heart blood, qi deficiency to blood stasis, qi depression to blood stasis card types
It carries out dialectical.(1) heart blood silt: primary symptom: colic pain uncomfortable in chest, sharp ache, fixation do not move.Minor symptom: sweating, palpitation and uneasiness, tongue
Purple dark, thready and hesitant pulse etc..It is diagnosable to be provided simultaneously with primary symptom 2~3 or primary symptom 1+minor symptom 2 or more persons.(2) syndrome of blood stasis due to qi deficiency:
Primary symptom: pectoralgia is uncomfortable in chest, spiritlessness and weakness, complexion are purple dark.Minor symptom: shortness of breath and palpitation, pale tongue be purple, weak pulse and it is puckery.It is provided simultaneously with 2 primary symptoms
Or to have 1 primary symptom+1~2 minor symptom person diagnosable.(3) syndrome of qi stagnation and blood stasis: primary symptom: pectoralgia is uncomfortable in chest, sharp ache, fixes not
It moves, fullness in chest and hypochondrium.Minor symptom: the purple dark, uneven pulse of palpitaition, tongue.It is diagnosable to be provided simultaneously with primary symptom 3 or primary symptom 2+minor symptom, 2 persons.
1.2.3 it is all meeting Western medicine diagnostic criteria and above-mentioned 3 differentiation of symptoms and signs for classification of syndrome of Chinese medicine to be included in case standard, the hospital stays
>=2 weeks, the age was in 40~75 years old unstable angina pectoris of coronary heart disease and the patient of signature informed consent form.
1.2.4 exclusion criteria (1) acute myocardial infarction AMI or acute myocardial infarction AMI is probably developed into, needs row Reperfu- sion
Curer；(2) age was in 40 years old or less or 75 years old or more patient；(3) gestation, breast feeding women and have drug allergy history person；(4)
There are the complication such as severe cardiac, liver, kidney, or is associated with other severe primary diseases, mental patient；(5) there is obvious digestion suction
Receive the chronic bowel dysfunction persons such as obstacle, more serious canker and the incomplete ileus；(6) it treats less than 2 weeks, during observation
That is discharge person.
Selected patients are randomly divided into observation group and control group by 1.3 treatment methods, and observation group 90 controls in routine of western medicine
It is added on the basis for the treatment of (Simvastatin, Isosorbide Mononitrate, aspirin, Low-molecular-weight Heparins Calcium, polarized solution) and exhausts fragrant analgesic therapy glue
(Tianshui hospital of traditional Chinese hospital Drug Manufacturing Room provide capsule, and recipe includes dragon's blood, santal, RADIX GINSENG ALBA, Poria cocos, asarum, borneol, amber, three
Seven；Function: spleen shield heart, Warming Yang and promoting blood circulation, analgesic therapy of promoting blood circulation are adjusted；Specification: 0.5g/；Usage: it 4 tablets/time, 3 times/day, is treated for one within 15 days
Journey.Control group 60, using western medicine routine treatment, medication is same as above, 15 days as one therapeutic course.It is preced with simultaneously during medication observation
Heart trouble health education, diet etc..
1.4 observation index
1.4.1 clinical endpoint: observe pretherapy and post-treatment patient's pectoralgia duration, seizure frequency, pain degree, palpitaition,
Uncomfortable in chest, shortness of breath, sweating, face lip cyanosis, tongue picture, vein amount to 10 symptom or signs, are judged as all in accordance with different syndrome type
Primary symptom and minor symptom are scored respectively.When wherein above-mentioned symptom or sign are primary symptom, respectively according to heavy, medium and light, without setting score value as 6
Divide, 4 points, 2 points, 0 point；When above-mentioned symptom or sign are minor symptom, respectively according to heavy, medium and light, without setting score value as 3 points, 2 points, 1
Divide, 0 point.Tongue picture, pulse condition heavy, medium and light, nothing are scored, according to it is very typical, than it is more typical, substantially conform to, do not meet to point.
1.4.2 pretherapy and post-treatment c reactive protein and low-density lipoprotein；C reactive protein is complete certainly using Hitachi HITACHI7080
Dynamic biochemical instruments measurement (kit is purchased from Beijing Li Deman Co., Ltd).Low-density lipoprotein is complete using Hitachi HITACHI7080
Automatic biochemical analyzer measurement (kit is purchased from Beijing Zhongsheng Beikong Biological Science & Technology Co., Ltd.).
1.4.3 safety indexes: patient's blood, urine, stool routine examination, hepatic and renal function and electrocardiogram are checked before and after treatment.
1.4.4 adverse reaction: patient has no adverse reaction during observation treatment.
1.5 efficacy assessment standards are commented referring to coronary heart disease curative effect in 2002 version " new Chinese medicine guideline of clinical investigations "
Calibration is quasi-.(1) effective: tcm clinical practice symptom, sign are obviously improved, and syndrome integral reduces >=70%；(2) effectively: tcm clinical practice
Symptom, sign take a favorable turn, and syndrome integral reduces >=30%；(3) invalid: tcm clinical practice symptom, sign are not improved, even
It aggravates, syndrome integral reduces < 30%.Calculation formula: Nimodipine method is used: [(integral one integrates after treating before treating)/treat foreset
Point] × 100%.
1.6 statistical method
It is handled using 13.0 software package of SPSS.Measurement data is indicated with mean ± standard deviation (X ± s)；Compare in group, between group
It is examined compared with using t, ranked data are analyzed using sum of ranks.
2. result
Pre-treatment score compares no statistics between the pretherapy and post-treatment total mark situation of 2.1 two groups of clinical symptoms compares two groups of groups
Meaning (P > 0.05) has significant meaning (P < 0.001) compared with pre-treatment score after the interior treatment of two groups of groups, controls between two groups of groups
Liao Hou integral contrast observation group is better than control group (P < 0.005).Specifically it is shown in Table 3.
The pretherapy and post-treatment total mark situation of 3 two groups of clinical symptoms of table compares
Note: observation group and control group comparison among groups, * P > 0.05 before treating；In two groups of groups after treatment compared with before treatment,
Δ P < 0.001；Compare after being treated between two groups of groups, #P < 0.005.
Situation is integrated before and after 2.2 two groups of each symptom treatments compares, observation group interior relatively with two groups of groups after treatment before treatment
Conspicuousness (P < 0.01) is all had to the improvement of each symptom, and control group is to palpitaition, shortness of breath, sweating, cyanotic lips, tongue picture, arteries and veins
As comparing before and after treatment no significant difference (P > 0.05), there were significant differences (P < 0.01) for the improvement of remaining symptom；Two groups after treatment
(P > 0.05) more not statistically significant to pectoralgia duration, episode frequency, pectoralgia degree, other symptoms, which improve, to be seen
It examines group and is superior to control group (P < 0.05).Specifically it is shown in Table 4.
4 two groups of table each pretherapy and post-treatment integral contrasts of clinical symptoms
Note: in pretherapy and post-treatment two groups of groups relatively, * P < 0.01；Two groups of comparison among groups after treatment,ΔP < 0.05.
2.3 two groups of curative effect situation comparative observation groups are compared with control group curative effect, and observation group's curative effect is substantially better than control group (Z
=0.4009, P < 0.05).Specifically it is shown in Table 5.
Two groups of curative effects compare (rank sum test) after table 5 is treated:
C reactive protein, low-density before the two groups of treatments of pretherapy and post-treatment situation of 2.4 two groups of c reactive proteins, low-density lipoprotein
There are no significant for lipoprotein levels difference (P > 0.05).Phase before c reactive protein, low-density lipoprotein and treatment after two groups of treatments
There is conspicuousness (P < 0.001) than difference；Compared after two groups of treatments, observation group's c reactive protein, low-density lipoprotein white level with
Control group has conspicuousness (P < 0.05) compared to difference；Specifically it is shown in Table 6.
6 two groups of table to the pretherapy and post-treatment c reactive protein of unstable angina pectoris of coronary heart disease patient, ldl ratio compared with
Note: the preceding two groups of comparison among groups for the treatment of, *, P > 0.05；After treatment compared with treating in preceding two groups of groups,Δ, P <
0.001；Two groups of comparison among groups after treatment,#, P < 0.005.
2.5 safeties and adverse reaction observation group duration of medication find no adverse reaction.Pretherapy and post-treatment blood, routine urinalysis
And hepatic and renal function is shown normally.
3. discussing
Unstable angina pectoris of coronary heart disease motherland medicine is referred to as " thoracic obstruction ", " angina pectoris ", and " Plain Questions numbness opinion " is said: " thoracic obstruction
Person's arteries and veins is obstructed ", illustrate that the pained interpretation of the cause, onset and process of an illness is obstruction of collaterals by blood stasis, not general rule pain." gold is deficient " cloud: " weak pulse at YANG and stringy pulse at YIN, i.e. chest obstruction with pain,
It is extremely empty to blame it by reason person ", disclosing pained illness not only has real example, also there is asthenic symptoms.It is one that comprehensive ancient Chinese medicine doctor, which discusses thoracic obstruction,
The card of asthenia in origin and asthenia in superficiality, weakened body resistance (heart qi deficiency and the deficiency of the heart-yin) are the internal causes of this disease, and the stagnation of the circulation of vital energy, blood stasis, turbid phlegm is the secondary factor of this disease.In
Medicine has significant progress, the extensive use of activating blood and removing stasis Method, Chinese medicine in the treatment of unstable angina pectoris of coronary heart disease at present
" blood stasis " " obstructed " and the thrombosis " atherosclerotic plaque is formed " in modern medicine understanding it is rather close.Think
Unstable angina pectoris of coronary heart disease uses activating microcirculation and removing stasis medicinal recipe due to caused by heart arteries and veins stasis blocking, has clinically achieved affirmative
Clinical efficacy.New Chinese medicine such as compound danshen dripping pills, suxiao jiuxin pills, Tongxinluo, danshen injections, XUESAITONG ZHUSHEYE etc.
Research and development opened up new therapy approach to the treatment of coronary heart disease, and achieve preferable curative effect.But current Chinese materia medica preparation is equal
The characteristics of being removed obstruction in channels to relieve pain with activating microcirculation and removing stasis medicinal as theoretical foundation and major function, having ignored coronary heart disease asthenia in origin and asthenia in superficiality, we pass through total
It ties the national distinguished veteran doctors of TCM experience that treatment coronary heart disease obtains for many years and grasps CDH most in conjunction with the experience essence of Wang Zhong blueness distinguished veteran doctors of TCM
New dynamic proposes the characteristic principle of reatment of " adjusting spleen shield heart, Warming Yang and promoting blood circulation ", develops preparation in leaving hospital meticulously and exhausts fragrant analgesic therapy capsule.
RADIX GINSENG ALBA in side, Poria cocos strengthening the spleen and replenishing qi, promoting blood circulation row arteries and veins, with up to the function of gas row then blood；Dragon's blood, pseudo-ginseng blood-circulation-invigovating stagnation resolvation, row of promoting blood circulation
Blood is removed obstruction in channels to relieve pain；Amber antitoxic heart-soothing and sedative, activating blood and promoting diuresis；Borneol, the qi-regulating of santal fragrance, coronary circulation-promoting pain-relieving；Asarum warming yang for activating qi-flowing is living
Blood；Full side is played altogether adjusts spleen shield heart, Warming Yang and promoting blood circulation, and the function for analgesic therapy of promoting blood circulation has the characteristics that treating both manifestation and root cause of disease.It is demonstrate,proved according to modern pharmacological research
Real: ginsenoside can promote cardiac muscle cell DNA synthesis and update, and improve energy metabolism of myocardial, reduce or eliminate oxygen radical,
Coronary artery dilator improves blood circulation [3], and stream in the outer Ca2+ of blocks cellular alleviates vascular smooth muscle spasmus, reduces blood pressure
[4].Amber plays the role of reducing thromboxane B2, improves the blood stasis of blood state of rat, and have tranquilizing effect.Radix Notoginseng increases the heart
Dirty coronary blood flow, reducing heart rate and increase myocardial contractive power [5].It is multiple that notoginseng total saponin can mitigate the low filling-of isolated rat heart
The release of cardiac muscle CPK and Ca2+ caused by filling, it is significant to protect SOD activity, reduce the generation of malonaldehyde, while some biochemical indicators
It has been shown that, notoginseng total saponin improve Tissue Blood with it to the protective effect of ischemic myocardium and supply, and antioxidation is related [6].
CRP is a kind of acute inflammation phase reactive protein, is generated by liver, become coronary heart disease risk factor it
One.Research finds that generation, development and the prognosis of the level and coronary heart disease of serum CA125 have direct relation.Stable angina cordis, shakiness
Sizing angina pectoris, myocardial infarction patient serum CA125 successively increase, it may be possible in artery atherosclerotic plaque itself extensively, seriously
Inflammatory tissue damage, cause plaque rupture, and then coronary occlusion [7] occur.It is risk of cardiovascular disease that CRP, which increases,
The strong determinant increased, the index as judging prognosis or even therapeutic effect are particularly useful [8].
By to 90 unstable angina pectoris of coronary heart disease Chinese medical discrimination category qi depressions to blood stasis, syndrome of blood stasis due to qi deficiency, the stagnation of the heart blood
The clinical observation of patient confirms, exhausts fragrant analgesic therapy capsule and affirms to unstable angina pectoris of coronary heart disease patient clinical curative effect, this research
It was found that the CRP of UAP patient is horizontal significantly raised, inflammatory reaction is prompted to have in the pathogenesis of unstable angina certain
Effect.Through after exhausting fragrant analgesic therapy capsule for treating blood CRP level be decreased obviously, to unstable angina pectoris of coronary heart disease patient C react
Albumen and low-density lipoprotein have a significant impact.Without obvious adverse reaction, trouble can more effectively be improved by sharing with modern Western medicine treatment
The clinical symptoms and prognosis of person.This research prompt exhausts fragrant analgesic therapy capsule and is conducive to unstable centering strand in the mechanism of action of anti-inflammatory aspect
The Morbidity control of pain, anti-inflammatory effect may be by improving endothelial function and blood coagulation state, reduce inflammatory mediator and
The expression of cell factor achievees the purpose that inhibit inflammation, stable patch with generating.
It is obvious to a person skilled in the art that invention is not limited to the details of the above exemplary embodiments, Er Qie
In the case where without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by appended power
Benefit requires rather than above description limits, it is intended that all by what is fallen within the meaning and scope of the equivalent elements of the claims
Variation is included within the present invention.
Claims (5)
1. a kind of coronary heart disease for the treatment of exhausts fragrant analgesic therapy capsule, which is characterized in that by weight include following components: Resina Draconis 10-
15 parts, 5-8 parts of santal, 5-8 parts of ginseng, 10-14 parts of Poria cocos, 4-6 parts of asarum, 1-3 parts of borneol, 5-7 parts of amber, Radix Notoginseng 10-18
Part.
2. treatment coronary heart disease according to claim 1 exhausts fragrant analgesic therapy capsule, which is characterized in that by weight include following
Component: 10 parts of Resina Draconis, 5 parts of santal, 5 parts of ginseng, 10 parts of Poria cocos, 4 parts of asarum, 1 part of borneol, 5 parts of amber, 10 parts of Radix Notoginseng.
3. treatment coronary heart disease according to claim 1 exhausts fragrant analgesic therapy capsule, which is characterized in that by weight include following
Component: 15 parts of Resina Draconis, 8 parts of santal, 8 parts of ginseng, 14 parts of Poria cocos, 6 parts of asarum, 3 parts of borneol, 7 parts of amber, 18 parts of Radix Notoginseng.
4. treatment coronary heart disease according to claim 1 exhausts fragrant analgesic therapy capsule, which is characterized in that by weight include following
Component: 14 parts of Resina Draconis, 7 parts of santal, 7 parts of ginseng, 9 parts of Poria cocos, 5 parts of asarum, 2 parts of borneol, 6 parts of amber, 15 parts of Radix Notoginseng.
5. the preparation method that treatment coronary heart disease according to claim 1 exhausts fragrant analgesic therapy capsule, which is characterized in that specifically include
Following steps: taking formula ratio Resina Draconis part, santal, ginseng, Poria cocos, asarum, borneol, and amber and the sieving of Radix Notoginseng milling are simultaneously uniform
Mixing, while mixed powder is added appropriate maltodextrin and mixes again, then subsequent dry-pressing granulation adds Magnesium Stearate proper quantity,
It is encapsulated, 0.5g/.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811034887.0A CN109045184A (en) | 2018-08-31 | 2018-08-31 | A kind of preparation method treated coronary heart disease and exhaust fragrant analgesic therapy capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811034887.0A CN109045184A (en) | 2018-08-31 | 2018-08-31 | A kind of preparation method treated coronary heart disease and exhaust fragrant analgesic therapy capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109045184A true CN109045184A (en) | 2018-12-21 |
Family
ID=64759951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811034887.0A Pending CN109045184A (en) | 2018-08-31 | 2018-08-31 | A kind of preparation method treated coronary heart disease and exhaust fragrant analgesic therapy capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109045184A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432393A (en) * | 2022-02-22 | 2022-05-06 | 黑龙江省济仁药业有限公司 | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method and application thereof |
| CN116999515A (en) * | 2023-06-06 | 2023-11-07 | 天水市中医医院(天水市中医研究所) | Traditional Chinese medicine composition for treating hypertension and application thereof |
-
2018
- 2018-08-31 CN CN201811034887.0A patent/CN109045184A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432393A (en) * | 2022-02-22 | 2022-05-06 | 黑龙江省济仁药业有限公司 | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method and application thereof |
| CN116999515A (en) * | 2023-06-06 | 2023-11-07 | 天水市中医医院(天水市中医研究所) | Traditional Chinese medicine composition for treating hypertension and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109045184A (en) | A kind of preparation method treated coronary heart disease and exhaust fragrant analgesic therapy capsule | |
| CN101810739B (en) | Anti-osteoarthritis Chinese medicament compound and use thereof | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN108938989A (en) | It is a kind of treat osteoporosis cover fennel essence bone-building up powder | |
| CN115177669B (en) | Traditional Chinese medicine composition with efficacy of treating myocardial bridge and application thereof | |
| CN104147346B (en) | It is a kind of to treat the anginal Chinese medicine compound prescription of coronary artery diffusivity lesion | |
| CN104225067B (en) | Chinese medicine composition, preparation method and purposes for treating postmenopausal osteoporosis | |
| CN103933334B (en) | Medicinal composition for treating pulmonary fibrosis, and preparation method and application thereof | |
| CN110201041A (en) | A kind of composition of activating microcirculation and removing stasis medicinal function of invigorating circulation and reducing blood fat | |
| CN101757527B (en) | Traditional Chinese medicine composition for treating nephritis and preparation method thereof | |
| CN106620707B (en) | A kind of pharmaceutical composition and its preparation method and application preventing and treating myocardial ischemia | |
| CN109674915A (en) | A kind of Chinese medicine and preparation method thereof for treating Osteoarthritis | |
| CN106728112A (en) | A kind of Chinese medicine composition for treating the protrasion of the lumbar intervertebral disci | |
| CN100453093C (en) | Medicine for transient cerebral ischemia attack and its preparation | |
| CN114377063B (en) | Traditional Chinese medicine composition for treating delayed fracture healing | |
| CN1233361C (en) | Traditional Chinese medicine composition for treating cardiovascular disease | |
| NL2029801B1 (en) | Method for preparing jiexiang dingtong capsule for treating coronary heart disease | |
| CN115844972B (en) | Navel patch for treating osteoporosis and preparation method thereof | |
| CN115192657B (en) | Traditional Chinese medicine preparation for treating type 2 diabetes kidney disease and application thereof | |
| CN109419844B (en) | Tibetan medicine composition for treating osteoarthritis pain | |
| CN107233427A (en) | A kind of Chinese medicine composition for preventing and treating PMO and preparation method thereof | |
| CN100353995C (en) | Pharmaceutical composition with functions of dispersing pathogenic wind, activating collaterals ,and clearing away toxin | |
| CN106727752A (en) | Treat pharmaceutical composition of synovitis and preparation method thereof | |
| CN1507906A (en) | Medicine for treating cardio-cerebro vascular disease and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181221 |